Barinthus Biotherapeutics (BRNS) Cash from Financing Activities (2020 - 2025)
Barinthus Biotherapeutics' (BRNS) quarterly Cash from Financing Activities came in at $2000.0 in Q1 2025, down 99.6% YoY from $503000.0 in Q1 2024, and down 99.76% on a QoQ basis from $837000.0 in Q4 2024.
Barinthus Biotherapeutics (BRNS) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Cash from Financing Activities data on file, last reported at $2000.0 in Q1 2025.
- Quarterly Cash from Financing Activities fell 99.6% year-over-year to $2000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $2000.0 (down 99.91% YoY) and the FY2025 annual result came in at $2000.0, down 99.91% from the prior year.
- Cash from Financing Activities fell to $2000.0 in Q1 2025, from $837000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $121.8 million in Q1 2021 to a low of -$1.4 million in Q3 2021.
- A 5-year average of $15.1 million and a median of $358000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 5277.78% in 2022, down 100.13% in 2022.
- Tracing BRNS's Cash from Financing Activities over 5 years: stood at $9000.0 in 2021, then soared by 5277.78% to $484000.0 in 2022, then tumbled by 77.48% to $109000.0 in 2023, then surged by 667.89% to $837000.0 in 2024, then plunged by 99.76% to $2000.0 in 2025.
- The last three Cash from Financing Activities figures came in at $2000.0 (Q1 2025), $837000.0 (Q4 2024), and $465000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 837,000.00 |
| Dec 31, 2024 | 837,000.00 |
| Sep 30, 2024 | 465,000.00 |
| Sep 30, 2024 | 465,000.00 |
| Jun 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 358,000.00 |
| Mar 31, 2024 | 503,000.00 |
| Mar 31, 2024 | 503,000.00 |
| Dec 31, 2023 | 109,000.00 |
| Dec 31, 2023 | 109,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 28,000.00 |
| Jun 30, 2023 | 28,000.00 |
| Mar 31, 2023 | 1.69 Mn |
| Mar 31, 2023 | 1.69 Mn |
| Dec 31, 2022 | 484,000.00 |
| Dec 31, 2022 | 484,000.00 |